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Abstract
Background: Oral epithelial dysplasia (OED) has a malignant potential. Therapeutic options for OED remain both
limited and without good evidence. Despite surgery being the most common method of treating OED, recurrence
and potentially significant morbidity remain problematic. Consequently, there has been much interest in non-
surgical treatments for OED. Cyclo-oxygenase (COX) up-regulation is known to occur in the dysplasia-carcinoma
sequence and evidence now exists that COX-2 is a prognostic marker of malignant transformation in OED. COX-
inhibitors are therefore considered a potential therapeutic strategy for treating this condition. We aimed to provide
both proof of principal evidence supporting the effect of topical COX inhibition, and determine the feasibility of
recruitment to an OED chemoprevention trial in the UK.
Methods: Recruitment of 40 patients with oral leukoplakia to 4 study arms was planned. The total daily dose of
Aspirin would increase in each group and be used in the period between initial diagnostic and follow-up biopsies.
Results: During the 15-month recruitment period, 15/50 screened patients were eligible for recruitment, and 13
(87%) consented. Only 1 had OED diagnosed on biopsy. 16 patients were intolerant of, or already taking Aspirin
and 16 patients required no biopsy. Initial recruitment was slow, as detection relied on clinicians identifying
potentially eligible patients. Pre-screening new patient letters and directly contacting patients listed for biopsies
improved screening of potentially eligible patients. However, as the incidence of OED was so low, it had little
impact on trial recruitment. The trial was terminated, as recruitment was unlikely to be achieved in a single centre.
Conclusion: This feasibility trial has demonstrated the low incidence of OED in the UK and the difficulties in
conducting a study because of this. With an incidence of around 1.5/100,000/year and a high proportion of those
patients already taking or intolerant of Aspirin, a large multi-centred trial would be required to fulfil the recruitment
for this study. The ability of topical non-steroidal anti-inflammatory drugs to modify COX and prostaglandin
expression remains an important but unanswered question. Collaboration with centres in other parts of the world
with higher incidences of the disease may be required to ensure adequate recruitment.
ISRCTN: 31503555.
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Background
Oral epithelial dysplasia (OED) is a potentially malignant
condition[1]. It often presents as oral leukoplakia, a
characteristic white lesion of the oral mucosa. Between
5-46% of these lesions will have dysplasia on histological
assessment[2-5]. OED has the potential to undergo ma-
lignant transformation to oral squamous cell carcinoma
(OSCC). There is wide variability in reported transform-
ation rates in the published literature from 5% to 36%
[6,7]. Our recent meta-analysis estimated the malignant
transformation rate to be around 12% (95% CI 8-18%)
[8]. Despite 5-year survival rates improving slightly over
the last 3 decades, progression to (OSCC) still carries a
poor prognosis[9].
Therapeutic options for managing dysplasia in the oral
cavity remain both limited and without a good evidence
base. There are three principal treatment strategies; sur-
veillance, chemoprevention and surgical[10]. Surgery is
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lesions, either by cold steel or LASER[11]. There are no
randomized controlled trials (RCTs) directly comparing
surgery to a surveillance policy, and there is no evidence
to prove that surgery reduces the risk of malignant
transformation in oral dysplasia[12]. Furthermore, recur-
rence rates after excision range between 10 and 35%.
Patients who undergo repeated resections are exposed to
potentially high levels of morbidity because of the ana-
tomical areas involved[7,13,14]. Consequently, there has
been an interest in non-surgical treatments for oral leu-
koplakia/dysplasia.
Clinical trials have examined a variety of chemopre-
vention strategies including the use of retinoids, bleo-
mycin, carotenoids (beta-carotene and lycopene) tea,
and systemic cyclo-oxygenase inhibitors. However, a
Cochrane review of RCTs in oral leukoplakia failed to
show any of them having a benefit over placebo in OED
[12]. Despite this, there has been continued interest in
the role of cyclo-oxygenase (COX) 1 and 2 and their
inhibitors in oral premalignant lesions. COX 1/2 are
known to be up-regulated in both oral dysplasia and
cancer along with other malignancies of the gastrointes-
tinal tract[15-18]. A study demonstrated a reduction in
prostaglandin expression within the dysplastic lesions
using systemic oral administration of a selective COX-2
inhibitor[19]. However, 2 separate trials of selective
COX-2 inhibitors failed to demonstrate any significant
effect in reducing the size or histological grade of oral
dysplastic lesions. No biochemical effect was examined
in these trials however[20,21]. Concerns over the cardio-
vascular side effect profile of systemic COX-2 inhibitors
have limited further research in this area.
We wished to explore the efficacy of topical oral COX
inhibitors on oral dysplasia. However, oral dysplasia is
thought to be an uncommon condition in the UK
[22,23]. Therefore, a clinical trial may be difficult to
undertake in the UK. Our pilot study aimed to deter-
mine the feasibility of recruitment to an oral dysplasia
chemoprevention trial in the UK, and to provide proof
of principal evidence of the effect of oral topical COX
inhibition on oral dysplastic lesions.Table 1 Patient eligibility criteria
Inclusion criteria
Clinically evident leukoplakia Histologically confir
Can attend for follow up Prior oral cancer
Requiring biopsy Patients on aspirin,
Over 18 years old Current treatment o
Able to give informed consent Active peptic ulcer
Not known to be pregnant History of aspirin in
History of associateMethods
Ethical approval from the West Midlands Research Eth-
ics Committee (08/H1208/49) and a clinical trial author-
isation from the MHRA were granted prior to the trial
commencing. The trial was designed as a multi-centre,
four-arm dose escalation, feasibility trial.
Patients
Patients attending outpatient departments with a clinic-
ally diagnosed white patch requiring a biopsy for histo-
logical diagnosis were identified. Those meeting the
inclusion and exclusion criteria outlined in Table 1 were
approached for consent to participate in the trial.
Sample size
We intended to recruit forty patients in total, with ten
patients sequentially allocated to each of the four study
arms.
Trial methodology
Consented patients underwent a biopsy of their lesion
by a clinician or a research fellow. Half of the biopsy
sample was sent for routine histological examination to
provide a clinical diagnosis. The other half was immedi-
ately snap frozen to −80° C in liquid nitrogen for mRNA
preservation. After histological assessment, those
patients without a diagnosis of dysplasia on this first bi-
opsy were reviewed in a follow-up clinic, and discharged
from the study due to ineligibility. Those with a diagno-
sis of any grade of dysplasia were given a six-week
course of Aspirin mouthwash and instructed on its use.
Participants were asked to gargle with the mouthwash
for at least one minute each time, two or three times
daily as specified, and to expectorate it fully. They were
also asked to record any adverse effects that they may
notice during the period of using the mouthwash. Eli-
gible patients would be sequentially allocated to one of
the four dosing schedules. The total daily dose of As-
pirin would increase sequentially in each group starting
with 150 mg/day. The dosing schedules are shown in
Table 2. Patients used the Aspirin for four to six weeks
until they returned for an excision biopsy of the lesion.Exclusion Criteria
med cancer
non− steroidal anti-inflammatory drugs or corticosteroids
f oral dysplasia involving topical or systemic treatment
duced asthma, stomach ulcers or aspirin sensitivity
d angioedema or urticaria, or suspected oral allergic reactions in the past.
Table 2 Aspirin dosing schedule for each of the 4 study arms
Group Dosing schedule Total Aspirin dose
1 One dispersible 75 mg tablet in 250 ml of water used as mouthwash for 60 seconds twice a day. 150 mg
2 Two dispersible 75 mg tablet in 250 ml of water used as mouthwash for 60 seconds twice a day. 300 mg
3 One dispersible 300 mg tablet in 250 ml of water used as mouthwash for 60 seconds twice a day. 600 mg
4 One dispersible 300 mg tablet in 250 ml of water used as mouthwash for 60 seconds three times a day. 900 mg
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way as the initial biopsy tissue with half of the specimen
used for routine histology to confirm the diagnosis and
the other half for research purposes. Following excision,
patients were followed up routinely in the head and neck
clinic.Outcome measures
The primary outcome measures were recruitment rates
and Prostaglandin E2 levels by ELISA between the pre-
and post-treatment biopsies as a measure of the activity
of the oral topical COX inhibition. Secondary outcome
measures included COX-1/COX-2 protein expression by
immunocytochemistry and western blotting, the com-
parison of WHO histological grade, the clinical size of
dysplastic lesion before and after treatment and the
safety and tolerability of an Aspirin mouthwash, assessed
by a patient diary.Analysis
Measurements outlined above were to be assessed on
the initial diagnostic biopsy, and then repeated on the
therapeutic excision specimen following 6 weeks of
treatment. This would allow paired comparisons to be
analysed using parametric and non-parametric methods,
adjusting for dose of Aspirin as appropriate. Local and
general tolerability along with side effects were assessed
by a patient questionnaire.Results
Screening
Initial detection of patients relied on clinicians identify-
ing those that were potentially eligible and notifying the
research team accordingly. Despite publicising the trial
widely, only 3 patients were consented in the initial
phase of the study. Two changes were therefore made
which improved screening and consent rates. The first
was pre-screening new patient letters and placing a re-
minder on the front of each set of notes. The second
involved directly contacting those patients already listed
for biopsies of the oral cavity. Despite improving screen-
ing of potentially eligible patients, as the rate of dysplasia
was so low, it had little impact on trial recruitment.Consented patients
Recruitment took place at one site (University Hospital
Coventry andWarwickshire NHS trust) between February
2010 and April 2011. During this period, 50 potential-
ly eligible patients were screened. 15 were deemed eli-
gible for recruitment, 13 (26%) of whom consented to
participate in the trial. 2 patients declined to consent,
citing a disinclination to participate in trials in general
rather than any specific concerns regarding this trial
protocol. Of the 13 consented, only 1 had dysplasia con-
firmed on their initial biopsy. The remaining 12 had
diagnoses of lichen planus (2 cases), candidiasis (1 case),
non-specific inflammation (8 cases) and one case of
squamous cell carcinoma. The patient who entered the
trial was allocated to trial group 1 and began the Aspirin
mouthwash, but failed to attend 4 further follow up
appointments, eventually returning after 4 months. As
this patient had only used the mouthwash for 2 weeks, it
was not felt to be beneficial to re-biopsy the lesion for
analysis in the trial.
Ineligible patients
For the 35 patients screened and found to be ineligible,
the main reasons were that the patients were already on
Aspirin (10 cases) were intolerant of Aspirin (6 cases) or
the lesion was not felt to require a diagnostic biopsy (16
cases). The trial was terminated after 15 months as the
trial steering committee considered recruitment of 40
patients was unlikely to be achieved with only a single
centre recruiting. No other sites could be opened for re-
cruitment due to the sponsor not wishing to sponsor an
interventional drug trial at other sites.
Missed patients
An audit was performed at the recruiting centre to as-
sess the actual number of patients being diagnosed with
oral dysplasia from the pathology database. 13 patients
were diagnosed with dysplasia in our centre during the
recruitment period. 5 were already taking or intolerant
of Aspirin and 3 had a prior diagnosis of head and neck
cancer. One patient was recruited in to the trial, with 4
potentially eligible patients missed. These patients all
presented during the early phase of the trial, when re-
cruitment relied on clinicians alerting the research team
to potentially eligible patients. No patients were missed
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method was improved as discussed previously.
Discussion
Failure of recruitment to this trial of topical COX-2 in-
hibitor for the treatment of OED is multifactorial. The
main reason was low numbers of eligible patients, partly
due to the low prevalence of the condition, but also to
the high numbers of patients either already taking or in-
tolerant of NSAIDs. Patient refusal did not appear to
play a role. Some of these potential reasons are discussed
in turn.
Low incidence of oral dysplasia
There is little data on the incidence or prevalence of oral
dysplasia. Following a workshop coordinated by the
WHO collaborating centre for oral cancer and pre-
cancer in the UK, a narrative review was produced exam-
ining the available epidemiological data[24]. The majority
of this data has been derived from community-based sur-
veys, predominantly from regions of rural India and from
institutional reviews and case series from European and
American centres. Nearly all primarily focus on the inci-
dence and prevalence of leukoplakia and erythroplakia
rather than specifically on the rates of dysplasia. This
data can occasionally be extracted however.
Large cohort studies were carried out in India through-
out the 1970’s. Two occupation specific studies (indus-
trial workers in Gujarat and Bombay policemen) found
annual incidence rates of 0.6 - 5.8 lesions/1000 per year
amongst non-tobacco user. The incidence was much
higher in tobacco users at 5.2 - 30.2/1000 per year
[25,26]. Similar large studies in India have estimated the
prevalence of leukoplakic lesions to be between 0.2% and
4.9%[27]. This difference in rates is thought to be be-
cause of regional variations in tobacco use. Slightly lower
prevalence rates of 0.7% to 1.4% have been shown in
European studies[28,29]. A study from 18 general dental
practices in England examined 2265 patients over the age
of 35. White or red lesions were found in 56 patients
(2.5%)[30]. A systematic review by Petti attempted to
pool the results from 23 published epidemiological stud-
ies. This analysis gave an estimated global prevalence of
leukoplakia of 1.49 - 2.6% (95% CI 1.72 - 2.74) whilst ac-
knowledging the high degree of heterogeneity between
studies[31]. This heterogeneity is a key reason for the dif-
ficulty in calculating the true scale of the disease burden
globally. In addition, many studies have a potential selec-
tion bias, as they are not representative of the overall
population from which the cases are drawn.
The proportion of leukoplakic lesions harbouring dys-
plasia is also unclear. Published rates range from 5% to
46%[2-5]. In the population served locally (approxi-
mately 1 million people), an audit of dysplasia casesdiagnosed over a one-year period has revealed 14 cases
of oral dysplasia, giving an annual incidence of around
1.4 per 100,000. This rate appears similar to those found
from other case series from the United Kingdom, where
between 6–9 cases per year were diagnosed, (the size of
the population these cases were drawn from is unclear,
but all were tertiary referral centres)[22,23,32].
Our audit suggests that a typical Head and Neck unit
in the UK may treat around one case of oral dysplasia
per month (1 – 1.5 per 100,000 patient population per
year) compared to the 10–15 Head and Neck Cancer
cases per month. Oral dysplasia is therefore rarely seen
in a teaching setting. This, combined with the ineligibil-
ity criteria, means any chance of recruitment would re-
quire large multi-centre trials in the UK.
High ineligibility
A large proportion of patients were ineligible because
they did not have a diagnosis of dysplasia, (27%) or did
not undergo biopsy as there was not felt to be a clinical
need to perform one (33%). A further 33% of potentially
eligible patients could not be recruited, as they were ei-
ther using, or intolerant of Aspirin. A change in trial de-
sign to allow previous or current use of systemic Aspirin
may have improved that aspect of recruitment, but may
also decrease the possibility of detecting an effect from
oral Aspirin mouthwash.
Incomplete patient capture
Continuous monitoring of patient recruitment is vital
for clinical trial success. This surveillance allows inter-
ventions to be undertaken thereby maximising eligible
patient enrolment. Slow initial recruitment in this study
was identified by the use of screening logs. All clinic let-
ters were then pre-screened to detect potentially eligible
patients and highlight these to the relevant clinicians.
This improved the numbers of patients consented. The
most successful method of screening however was iden-
tifying patients on a waiting list for diagnostic biopsy. A
dedicated list for outpatient biopsies further helped
identification.
Opening of other trial sites
Other sites for trial recruitment were identified. Despite
willingness on the part of those centres, the local Re-
search and Development department acting as trial
sponsor declined to give approval for the trial to be
opened at any other sites as this was the first drug trial
to be sole-sponsored by them.
Conclusion
This phase I feasibility trial has demonstrated difficulties
in conducting a study on this condition in a single insti-
tution in the UK, probably due to the low incidence of
Nankivell et al. Head & Neck Oncology 2012, 4:40 Page 5 of 5
http://www.headandneckoncology.org/content/4/1/40oral dysplasia. With an incidence of only around 1 to 1.5
per 100,000 per year, and a high proportion of those
patients already taking or intolerant of Aspirin, a large
multi-centred trial would be required to fulfil the re-
cruitment for this study. The question of the ability of
topical non-steroidal anti-inflammatory drugs to modify
COX and prostaglandin expression remains an import-
ant but unanswered question. Collaboration with centres
in other parts of the world with higher incidences of the
disease, such as India, may be a viable solution and is
currently being undertaken by this group.
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